Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (QUATTRO)

15 de junio de 2017 actualizado por: EPS Corporation

A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer

The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.

Descripción general del estudio

Descripción detallada

This is a single-arm, multicentre phase II study evaluating the efficacy and safety of Bevacizumab (BV) in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al. ASCO2013) as first-line treatment for Japanese metastatic colorectal cancer patients.

This study is composed two steps because of collecting safety issue in Japanese patient.

As First step (Step 1), It assess on the initial safety information in ten Japanese patients of the end of 2nd cycle. it is evaluated by DMC.

In parallel with the confirmation of the initial safety issue, register up to 65 cases in total and Step 1 patient, to evaluate the efficacy and safety (Step2).

Tipo de estudio

Intervencionista

Inscripción (Actual)

69

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Tokyo
      • Shinjuku, Tokyo, Japón, 162-0814
        • EPS Corporation

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Written Informed consent.
  2. Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.
  3. Not resectable metastatic colorectal cancer
  4. Age at enrollment is >= 20 and <= 75 years
  5. ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years
  6. One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis.
  7. Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.)
  8. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed.

    Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+

  9. UGT1A1 genotype tested. Categorized into Wild or single Hetero.

Exclusion Criteria:

  1. Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field.
  2. Untreated brain metastases or spinal cord compression or primary brain tumors.
  3. History of CNS disease.[except for asymptomatic Lacunar stroke]
  4. Requiring chronic systemic corticosteroid treatment.
  5. Current or recent ongoing treatment with anticoagulants.
  6. Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication.
  7. Treatment with any investigational drug within 4 weeks.
  8. Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea, >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases.
  9. Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure.[except for implantation of central venous catheter and port system.]
  10. Lack of physical integrity of the upper gastrointestinal tract.
  11. Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males.
  12. Hepatitis B or hepatitis C. Evidence of HIV infection.
  13. Previous Chemotherapy for other organs.
  14. Other active co-existing malignancies.
  15. History / Presence of thrombosis within 1 year requiring medication.
  16. History / Presence of paralytic ileus, obstruction or gastrointestinal perforation.
  17. Malignant coelomic fluid required drainage.
  18. History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications.
  19. History of fluoropyrimidine severe side effects caused by DPD defect.
  20. Interstitial pneumonitis or pulmonary fibrosis.
  21. Evidence or requiring systemic treatment for Infectious disease.
  22. Patient who is judged by the investigator to be inappropriate for study participation for any reason.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: FOLFOXIRI plus bevacizumab

Induction therapy is followed by the maintenance therapy.

[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.

[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.

Dado IV
Otros nombres:
  • BV
Dado IV
Otros nombres:
  • L-OHP
Dado IV
Otros nombres:
  • 5-FU
Dado IV
Otros nombres:
  • CPT-11
Dado IV
Otros nombres:
  • I LV

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-free survival (PFS) at 10 months
Periodo de tiempo: PFS rate at 10 months from study entry

PFS by investigator-reported measurements according to CT image. PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.

PD was defined as Overall Response by RECIST criteria v1.1 according to CT image.

PFS rate at 10 months from study entry

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Response rate (RR) by central review.
Periodo de tiempo: Up to 18 months
Response evaluation was performed according to RECIST criteria v1.1.
Up to 18 months
Response rate (RR) by investigator-reported measurements.
Periodo de tiempo: Up to 30 months
Response evaluation was performed according to RECIST criteria v1.1.
Up to 30 months
PFS by central review according to CT image.
Periodo de tiempo: Up to 18 months
PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.
Up to 18 months
Overall survival (OS)
Periodo de tiempo: Up to 30 months
OS was calculated from the day of registration in this study to death from any cause.
Up to 30 months
Efficacy by RAS status ; RR,PFS,OS
Periodo de tiempo: Up to 30 months
RR,PFS,OS according to tumor RAS status.
Up to 30 months
Incidence of adverse events
Periodo de tiempo: Up to 30 months
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. All adverse events was collected in duration from starting treatment to whichever shorter "after 30 days from withdrawal treatment" or "later treatment was started".
Up to 30 months
Time to treatment-failure
Periodo de tiempo: Up to 30 months
Up to 30 months
Completion rate in Induction treatment
Periodo de tiempo: Up to 30 months
Up to 30 months
Relative Dose Intensity
Periodo de tiempo: Up to 30 months
Up to 30 months
Treatment duration
Periodo de tiempo: Up to 30 months
Up to 30 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Takeshi Kato, M.D., Ph.D, Department of Surgery, National Hospital Organization Osaka National Hospital.
  • Investigador principal: Akiyoshi Kanazawa, M.D., Ph.D, Department of Surgery, Shimane Prefectural Central Hospital.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2014

Finalización primaria (Actual)

1 de febrero de 2017

Finalización del estudio (Actual)

1 de febrero de 2017

Fechas de registro del estudio

Enviado por primera vez

12 de septiembre de 2014

Primero enviado que cumplió con los criterios de control de calidad

19 de septiembre de 2014

Publicado por primera vez (Estimar)

22 de septiembre de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de junio de 2017

Última actualización enviada que cumplió con los criterios de control de calidad

15 de junio de 2017

Última verificación

1 de junio de 2017

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir